Azacitidine (DRLA) TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: azacitidine
Pack: Azacitidine (DRLA) 100 mg powder for injection, 1 vial
Brand name
(ARTG)
: AZACITIDINE-DRLA azacitidine 100 mg powder for injection vialWhat this medicine is used for
(ARTG)
AZACITIDINE-DRLA is indicated for the treatment of patients with intermediate-2 and high-risk Myelodysplastic Syndromes (MDS) according to the International Prognostic Scoring System (IPSS), Chronic Myelomonocytic Leukemia (CMMoL (10-29 percent marrow blasts without Myeloproliferative Disorder)), Acute Myeloid Leukemia (AML) with 20-30 percent blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO), in whom allogenic stem cell transplantation is not indicated.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, powder for
- Intravenous Infusion
- White to off white lyophilized powder in a sealed vial
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Shelf lifetime is 3 Years.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 100 mg pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient azacitidine
This medicine is not considered safe during pregnancy. You should discuss this medicine with your doctor or pharmacist. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
